Thomas E. Witzig, M.D.
Dr. Witzig has research interests in Hodgkin and non-Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia. His laboratory research centers around the study of new agents that interfere with signal transduction pathways in lymphoma and myeloma cells. This has led to clinical trials of new agents that focus on the PI3 kinase signal transduction pathway. These agents include temsirolimus and everolimus. He has also been involved in some of the first studies of lenalidomide for lymphoma. He has a long-standing interest in radioimmunotherapy and is conducting new research that combines immunomodulatory agents with Zevalin radioimmunotherapy.
Department of Internal Medicine
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.